Screening for Primary Aldosteronism in Hypertension With 24-hour URinary aLdosterone

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-15

Study Completion Date

2024-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational study compares the positivity rates of two tests for screening for primary aldosteronism: plasma aldosterone renin ratio and 24-hour urine aldosterone in patients with young-onset hypertension with or without other clinical features of primary aldosteronism.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Diagnostic Performance of 24-hour Urinary Aldosterone for Primary Aldosteronism

NCT06236698

Primary Aldosteronism Hypertension

COMPLETED

Diagnosing Variable Primary Aldosteronism.

NCT05765786

Primary Aldosteronism High Blood Pressure

RECRUITING

Multi-omics Studies of Primary Aldosteronism

NCT07111351

Primary Aldosteronism

RECRUITING

Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension

NCT05925569

Primary Aldosteronism Resistant Hypertension Secondary Hypertension +3 more

ACTIVE_NOT_RECRUITING NA

Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease

NCT06190158

Type 2 Diabetes Chronic Kidney Diseases

RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Plasma aldosterone and renin measurements are subject to significant intra-individual variability, including variation related to posture, time of day and sodium balance. Aldosterone secretion is not constant and may be subject to diurnal variation. As such one-off testing of ARR, does not consider the salt status of the individual necessitating repetition of tests to ensure false negative or false positive test results are ruled out. The value of accumulated aldosterone in a 24-hour sample has the advantage that it does not depend on circadian variation. This pilot observational study will help establish the positivity rates of both standard plasma aldosterone renin ratio and 24-hour urine aldosterone, and the degree to which they correlate but will help establish if untargeted screening in young-onset hypertension is feasible and test the robustness of current standard guidelines for primary aldosteronism screening and case confirmation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Primary Aldosteronism Urine Aldosterone

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A patient will be eligible for inclusion in this trial only if all of the following criteria apply:

* Aged 18 years and above.
* Meets NICE criteria for a diagnosis of hypertension with an age of onset of hypertension between 18-60 years.
* For cohort 2 (suspected primary aldosteronism): resistant hypertension, and/or hypertension with spontaneous or diuretic-induced hypokalaemia, and/or hypertension.

Exclusion Criteria

* • Severe hypertension (sustained blood pressure of \>200/110 mmHg) or a history of known secondary hypertension other than PA.

* Contraindications to confirmatory testing with saline infusion or oral salt loading test as per standard clinical criteria such as known clinical diagnosis of heart failure, and/or chronic kidney disease stage 3b.
* Known Pregnancy or breast feeding.
* Lack of informed consent.
* Any medical condition deemed unsuitable by investigator for participation in the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No